Iulian Alin Popescu

Dr. Iulian Alin Popescu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
IPIulian Alin Popescu
Iulian Alin Popescu
SGSimina Gaman
Simina Gaman
CNCarmen Elena Niculescu
Carmen Elena Niculescu
NANiculescu Stefan Adrian
Niculescu Stefan Adrian
CPCristina Popescu
Cristina Popescu
Cyclodextrin (CD)-based drug delivery systems have emerged as a promising strategy to overcome limitations commonly encountered in antidepressant therapy, including low bioavailability, poor solubility, and suboptimal penetration of the blood–brain barrier. This review synthesizes current evidence demonstrating that complexing various classes of antidepressants—such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and atypical antidepressants—with β-CD or its derivatives significantly enhances drug solubility and stability. In addition, encapsulation with CDs can diminish systemic toxicity and improve pharmacokinetics, thereby helping to optimize dosage regimens and reduce adverse effects. Analysis of published in vitro and in vivo studies indicates that CD formulations not only boost therapeutic efficacy but also enable sustained or targeted release, which is critical for drugs requiring precise plasma and tissue concentrations. When compared to other carriers (e.g., liposomes, polymeric nanoparticles, dendrimers), CD-based systems often stand out for their ease of formulation, biocompatibility, and cost-effectiveness, although limited drug-loading capacity can be a drawback. We recommend expanding in vivo trials to substantiate the clinical benefits of CD–antidepressant complexes, particularly for treatment-resistant cases or specific subpopulations (e.g., elderly and pediatric patients). Additional investigations should also explore hybrid systems—combining CDs with advanced nano- or macroparticles—to amplify their advantages and address any limitations. Ultimately, integrating CDs into antidepressant regimens holds substantial potential to refine therapy outcomes, reduce adverse events, and pave the way for more personalized, effective interventions for depression.

Verified
Journal Article
Open access
PDF file
RARoxana Viorela Ahritculesei
Roxana Viorela Ahritculesei
BLBOLDEANU LIDIA
BOLDEANU LIDIA
DCDaniel Cosmin Caragea
Daniel Cosmin Caragea
IVIonela Mihaela Vladu
Ionela Mihaela Vladu
Diana ClenciuDiana Clenciu
Diana Clenciu
CVCristin Constantin Vere
Cristin Constantin Vere
Systemic inflammation has an important role in the prognosis and progression of many chronic diseases, including diabetes (T2DM). This retrospective study aimed to evaluate inflammatory status by determining the serum inflammatory biomarkers (PTX3, hs-CRP, TNF-α, and IL-6) and new indices, like the mean corpuscular volume (MCV) to lymphocyte ratio (MCVL) and cumulative inflammatory index (IIC), in a cohort of patients with prediabetes (PreDM) and newly diagnosed T2DM. We also wanted to assess the association with clinical parameters and different obesity-related indices, to identify possible correlations and to evaluate the diagnostic accuracy of the biomarkers using ROC curve analysis. In this study, we included 60 patients diagnosed with T2DM and 30 patients with PreDM. The ELISA method was applied. Elevated PTX3, hs-CRP, TNF-α, and IL-6 levels were found in T2DM patients compared to preDM patients. An independent relationship was found between PTX3, hs-CRP, and different obesity-related indices in patients with preDM and T2DM. The MCVL index exhibited an inverse trend proportional to the rising levels of HbA1c in the T2DM group. Spearman’s analysis revealed in the T2DM group that the PTX3 values correlated much better with IIC (rho = 0.445, p-value = 0.014) and MCVL (rho = 0.338, p-value = 0.048). Hs-CRP values expressed moderate-to-weak correlations with IIC and MCVL in both groups. Additionally, ROC analysis showed that the PTX3 (AUC was 0.720; p = 0.003; cut-off value 1888.00 pg/mL, with 67.60% sensitivity and 73.30% specificity) and MCVL index (AUC was 0.677; p = 0.047; cut-off value 39.60, with 63.30% sensitivity and 66.70% specificity) have a good, accurate diagnosis compared with IL-6 (AUC was 0.866; p < 0.0001; cut-off value 40.30 pg/mL, with 100.00% sensitivity and 60.00% specificity). IIC showed 61.70% sensitivity and 60.00% specificity, with an AUC of 0.572, p = 0.027 and a cut-off value of 2.35. PTX3 and MCVL can serve as independent predictor factors in the inflammatory status in preDM and T2DM patients, supporting their potential as biomarkers for T2DM management and future research.

11 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CPCristina Popescu
Cristina Popescu
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
MPMonica Puticiu
Monica Puticiu
VBVlad Ionut Belghiru
Vlad Ionut Belghiru
MBMihai Banicioiu
Mihai Banicioiu
IPIulian Alin Popescu
Iulian Alin Popescu
Background: This study presents a comprehensive analysis of cholesteatoma of the middle ear, focusing on its clinical presentation, diagnostic imaging, and treatment outcomes. Cholesteatomas are defined by the keratinized squamous epithelium within the middle ear, leading to significant bone erosion, often affecting the ossicular chain and surrounding structures. Methods: The study explores various mechanisms involved in cholesteatoma progression, including enzymatic lysis, inflammatory responses, and neurotrophic disturbances. The study conducted a retrospective clinical and statistical review of 580 patients over a 20-year period (2003–2023), highlighting the role of advanced imaging, including computed tomography (CT) and diffusion-weighted magnetic resonance imaging (DWI), in preoperative planning and postoperative follow-up. Results: Findings revealed that early detection and intervention are crucial in preventing severe complications such as intracranial infection and hearing loss. Surgical treatment primarily involved tympanoplasty and mastoidectomy, with a recurrence rate of 1.55% within two years. The study underscores the importance of integrating imaging advancements into clinical decision-making to enhance patient outcomes and suggests further investigation into molecular mechanisms underlying cholesteatoma progression and recurrence. Histopathological and microbiological analysis was performed to identify pathological patterns and microbial agents. Conclusions: The study highlights the importance of early diagnosis and intervention to prevent complications such as intracranial infections and permanent hearing loss, while also emphasizing the role of advanced imaging techniques in the management and long-term monitoring of cholesteatoma patients.

13 September 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
MSMaria Madalina Singer
Maria Madalina Singer
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
CPCristina Popescu
Cristina Popescu
KRKristina Radivojević
Kristina Radivojević
Luciana Teodora RotaruLuciana Teodora Rotaru
Luciana Teodora Rotaru
CSCristina Elena Singer
Cristina Elena Singer
Antibiotic misuse in Romania has exacerbated the issue of antibiotic resistance, as patients often use antibiotics without proper medical consultation. This study aimed to assess the resistance of prevalent bacteria to different antibiotics. In this observational study conducted over six months, we analyzed 31 pediatric patients aged from 12 days to 13 years using the disk diffusion method. We identified 31 bacterial isolates, including 8 Gram-negative and 8 Gram-positive strains, with the most common being Pseudomonas aeruginosa, Escherichia coli, Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, Streptococcus species, and Elizabethkingia meningoseptica. Our findings revealed that the most effective antibiotics were linezolid, ertapenem, and teicoplanin. In contrast, nearly all tested bacteria exhibited resistance to penicillin, followed by oxacillin and ampicillin. Resistance to cephalosporins varied with generation, showing higher resistance to lower-generation cephalosporins. The study highlights significant antibiotic resistance among common bacterial pathogens in Romanian pediatric patients, emphasizing the urgent need for controlled antibiotic use and alternative treatment strategies to combat this growing issue. Effective antibiotics such as linezolid and ertapenem offer potential solutions, whereas reliance on penicillin and lower-generation cephalosporins is increasingly futile.

13 November 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
CPCristina Popescu
Cristina Popescu
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
MPMihaela Popescu
Mihaela Popescu
IPIulian Alin Popescu
Iulian Alin Popescu
CSCristina Elena Singer
Cristina Elena Singer
Background/Objectives. Otomastoiditis, an inflammatory condition affecting the middle ear and mastoid cells, poses significant risks for hearing impairment. This study aimed to analyze the clinical presentations, anatomical variations, and audiometric outcomes associated with acute and chronic otomastoiditis over a five-year period at the ENT Clinic of the Clinical County Emergency Hospital of Craiova. Methods. A retrospective clinical–statistical analysis was conducted on 145 patients aged 2 to 78 years, who were treated for otomastoiditis. The study involved a comprehensive review of clinical and audiometric data, with a focus on the type of hearing loss (conductive or mixed), audiometric thresholds, and the relationship between the anatomical form of the disease and the severity of hearing loss. Results. The majority of cases (93.83%) were chronic otomastoiditis, with 66.89% of patients presenting with mixed hearing loss and 33.10% with conductive hearing loss. Audiometric assessments revealed significant air conduction deficits, particularly at low and mid-range frequencies, with losses averaging 50–55 dB in cases of conductive hearing loss. Chronic cases demonstrated notable bone conduction impairments, indicating progressive cochlear damage. Statistical analysis identified a moderate correlation between the anatomical form of the disease and the severity of hearing loss, particularly in patients with cholesteatomatous-suppurative forms. Conclusions. This study underlines the critical need for the early and precise diagnosis of otomastoiditis, supported by audiometric evaluations. Our findings emphasize the substantial risk of progressive cochlear damage in chronic cases, underscoring the necessity for timely intervention to mitigate long-term hearing loss. These results offer valuable insights for clinicians, potentially guiding improved therapeutic approaches and contributing to enhanced patient outcomes in managing chronic otomastoiditis.

7 July 2025
Verified
Book Chapter
Open access
PDF file
DHDiana Ruxandra Hădăreanu
Diana Ruxandra Hădăreanu
CFCristina Florescu
Cristina Florescu
AMAnca Mihu-Marinescu
Anca Mihu-Marinescu
VGVeronica Gheorman
Veronica Gheorman
EMEdme Roxana Mustafa
Edme Roxana Mustafa
VBViorel Biciusca
Viorel Biciusca
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease globally and is now recognized as a key cardiometabolic disorder. Beyond hepatic involvement, MASLD is independently associated with increased risks of coronary artery disease, stroke, arrhythmias, and heart failure, even after adjusting for traditional cardiovascular risk factors. Its pathophysiology involves insulin resistance, visceral adiposity, systemic inflammation, and oxidative stress, which collectively contribute to both hepatic fibrosis and cardiovascular disease (CVD). Diagnostic strategies have evolved to include non-invasive tools—such as the Fibrosis-4 Index and Enhanced Liver Fibrosis test, transient elastography, NT-proBNP, coronary artery calcium scoring, and echocardiography—to facilitate early identification of patients at dual hepatic and cardiovascular risk. Complementing these efforts, a novel pathophysiological staging framework for systemic metabolic disorder has been proposed to stratify disease severity and personalize treatment approaches. Management is increasingly multidimensional, combining lifestyle intervention with pharmacologic therapies such as GLP-1 receptor agonists, SGLT2 inhibitors, statins, and novel agents like resmetirom. Given the shared pathophysiological mechanisms between MASLD and CVD, integrated care approaches across hepatology, cardiology, and endocrinology are essential. Recognizing MASLD as a systemic disease enables earlier interventions that may prevent both hepatic progression and adverse cardiovascular outcomes.